{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:53:14Z","timestamp":1776228794748,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.leukres.2026.108207","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:18:37Z","timestamp":1774023517000},"page":"108207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling study"],"prefix":"10.1016","volume":"164","author":[{"given":"Yuya","family":"Arai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3031-9990","authenticated-orcid":false,"given":"Seiichiro","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5725-7187","authenticated-orcid":false,"given":"SungGi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goichi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-3370","authenticated-orcid":false,"given":"Yukinori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.leukres.2026.108207_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2026.108207_bib2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.leukres.2026.108207_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108207_bib4","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.leukres.2026.108207_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","article-title":"KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation","volume":"13","author":"Miettinen","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"22","key":"10.1016\/j.leukres.2026.108207_bib6","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.leukres.2026.108207_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.21037\/tp-20-102","article-title":"Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis","volume":"9","author":"Fan","year":"2020","journal-title":"Transl. Pedia"},{"issue":"1","key":"10.1016\/j.leukres.2026.108207_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2026.108207_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells","volume":"174","author":"Ogawa","year":"1991","journal-title":"J. Exp. Med"},{"issue":"7","key":"10.1016\/j.leukres.2026.108207_bib10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/leu.2014.4","article-title":"High number of additional genetic lesions in acute myeloid leukemia with t(8;21)\/RUNX1-RUNX1T1: frequency and impact on clinical outcome","volume":"28","author":"Krauth","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2026.108207_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00277-012-1580-5","article-title":"KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1\/RUNX1T1 rearrangement","volume":"92","author":"Kim","year":"2013","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108207_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/cas.15746","article-title":"Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots:\u00a0HM-Screen-Japan 01","volume":"114","author":"Hosono","year":"2023","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.leukres.2026.108207_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12185-024-03895-w","article-title":"A practice-oriented genome profiling study for acute myeloid leukemia using the noval HANDLE system: HM-screen-JAPAN02","volume":"121","author":"Arai","year":"2025","journal-title":"Int J Hematol"},{"issue":"20","key":"10.1016\/j.leukres.2026.108207_bib14","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108207_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/bloodadvances.2019000168","article-title":"An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1","volume":"4","author":"Al-Harbi","year":"2020","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.leukres.2026.108207_bib16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.exphem.2014.07.267","article-title":"The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell","volume":"42","author":"Shima","year":"2014","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108207_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/leu.2014.179","article-title":"Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1\/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors","volume":"29","author":"Wichmann","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2026.108207_bib18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S0002-9440(10)65419-3","article-title":"Activating c-kit gene mutations in human germ cell tumors","volume":"154","author":"Tian","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.leukres.2026.108207_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.exphem.2020.10.005","article-title":"RUNX1\/ETO and mutant KIT both contribute to programming the transcriptional and chromatin landscape in t(8;21) acute myeloid leukemia","volume":"92","author":"Chin","year":"2020","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2026.108207_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.exphem.2017.05.003","article-title":"D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia","volume":"52","author":"Omori","year":"2017","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108207_bib21","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108207_bib22","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108207_bib23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.27547","article-title":"Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase\u00a0II\u00a0Clinical Trial","volume":"100","author":"Cairoli","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108207_bib24","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","article-title":"Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial","volume":"32","author":"Paschka","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2026.108207_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:00:41Z","timestamp":1776225641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"alternative-id":["S0145212626000512"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108207","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108207"}}